Lv1
54 积分 2023-11-15 加入
Pharmacokinetics and Metabolism of ARV‐393, a BCL6 PROTAC Degrader, in Dogs by UPLC–MS/MS and UPLC‐Q‐Exactive Orbitrap‐HRMS
10小时前
已完结
NX-5948: a Bruton’s tyrosine kinase degrader in Ph. Ia/Ib for patients with advanced B-cell malignancies
1天前
已完结
Lessons learned in linking PROTACs from discovery to the clinic
4天前
已完结
Design and optimization strategies of PROTACs and its Application, Comparisons to other targeted protein degradation for multiple oncology therapies
4天前
已完结
Allosteric inhibition of JAK2 with lysine-reactive compounds that bind the pseudokinase domain
6天前
已完结
The Medicinal Chemistry and Therapeutic Potential of LRH-1 Modulators
11天前
已完结
Discovery of novel indole derivatives as LRH-1 antagonists for the treatment of castration resistant prostate cancer
12天前
已完结
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3
21天前
已完结
“Enhancing Oral Drug Absorption: Overcoming Physiological and Pharmaceutical Barriers for Improved Bioavailability”
22天前
已完结
Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy
28天前
已完结
皖公网安备34019202002308
